HC Wainwright Issues Positive Outlook for Neurogene Earnings

Neurogene Inc. (NASDAQ:NGNE) – Analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Neurogene in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.00) per share for the quarter, up from their previous estimate of ($1.04). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.16) EPS.

NGNE has been the subject of several other research reports. Lifesci Capital initiated coverage on shares of Neurogene in a report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price for the company. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Canaccord Genuity Group initiated coverage on Neurogene in a research note on Friday, February 27th. They issued a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Neurogene Stock Performance

Neurogene stock opened at $19.30 on Monday. The company’s 50 day simple moving average is $19.55 and its 200-day simple moving average is $21.69. Neurogene has a 1 year low of $6.88 and a 1 year high of $37.27. The company has a market capitalization of $300.50 million, a price-to-earnings ratio of -4.55 and a beta of 1.53.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.08.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,045 shares of Neurogene stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the transaction, the chief financial officer owned 105,798 shares in the company, valued at approximately $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the sale, the insider directly owned 30,497 shares in the company, valued at approximately $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 9.92% of the company’s stock.

Institutional Trading of Neurogene

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its holdings in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. grew its stake in Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after purchasing an additional 1,232 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Neurogene during the 4th quarter worth about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Neurogene in the 4th quarter valued at about $165,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.